The startup specializes in genomics sequencing focused on non-European genomes, utilizing modern and ancient DNA analysis across various sequencing platforms. By providing a diverse genomic database and biobank, the company enables pharmaceutical firms to enhance drug development through insights into disease predisposition and pharmacogenomics.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current pharmaceutical drug development relies heavily on genomic data primarily from European populations, neglecting the genetic diversity of other ethnic groups. This lack of representation can lead to less effective or even harmful treatments for non-European individuals.
Solution
CariGenetics addresses this disparity by focusing on genomic sequencing and analysis of Caribbean populations, a region with a uniquely diverse genetic makeup. By building a comprehensive genomic database and biobank specific to the Caribbean, CariGenetics enables pharmaceutical companies to develop more targeted and effective drugs for individuals of Caribbean descent and other underrepresented groups. The company's research aims to identify genetic markers associated with disease predisposition, pharmacogenomics, and ancestry, providing valuable insights for personalized medicine. CariGenetics also empowers local scientists and community members to participate in research, fostering trust and ensuring ethical data handling.
Target Audience
CariGenetics serves pharmaceutical companies seeking diverse genomic data for drug development, healthcare providers aiming to deliver personalized medicine, and individuals of Caribbean descent interested in understanding their ancestry and health risks.
Features
- Genomic sequencing and analysis of non-European genomes, with a focus on Caribbean populations
- Development of a diverse genomic database and biobank
- Identification of novel genetic markers for disease predisposition and pharmacogenomics
- Oxford Nanopore long-read sequencing for comprehensive genetic and epigenetic analysis
- Bio-NFTs (Non-Fungible Tokens) to ensure participant ownership and control of their genetic data
- Local data storage in a private cloud within the Caribbean
- Partnerships with local researchers and healthcare providers to build trust and capacity
- Consumer genetic testing for ancestry, health, wellness, and lifestyle insights